Publication: Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin
| dc.contributor.author | Weerawat Manosuthi | en_US |
| dc.contributor.author | Somnuek Sungkanuparph | en_US |
| dc.contributor.author | Ammarin Thakkinstian | en_US |
| dc.contributor.author | Sasivimol Rattanasiri | en_US |
| dc.contributor.author | Achara Chaovavanich | en_US |
| dc.contributor.author | Wisit Prasithsirikul | en_US |
| dc.contributor.author | Sirirat Likanonsakul | en_US |
| dc.contributor.author | Kiat Ruxrungtham | en_US |
| dc.contributor.other | Thailand Ministry of Public Health | en_US |
| dc.contributor.other | Mahidol University | en_US |
| dc.contributor.other | The HIV Netherlands Australia Thailand Research Collaboration | en_US |
| dc.contributor.other | Bamrasnaradura Infectious Disease Institute | en_US |
| dc.date.accessioned | 2018-08-20T07:01:18Z | |
| dc.date.available | 2018-08-20T07:01:18Z | |
| dc.date.issued | 2006-07-15 | en_US |
| dc.description.abstract | Seventy human immunodeficiency virus (HIV)-infected patients receiving rifampicin and 70 HIV-infected patients not receiving rifampicin were enrolled to receive 400 mg of nevirapine-based highly active antiretroviral therapy per day. Mean plasma nevirapine levels at 8 and 12 weeks were lower in patients receiving rifampicin (P = .048). However, virological and immunological outcomes at 24 weeks were not different between the 2 groups (P > .05). © 2006 by the Infectious Diseases Society of America. All rights reserved. | en_US |
| dc.identifier.citation | Clinical Infectious Diseases. Vol.43, No.2 (2006), 253-255 | en_US |
| dc.identifier.doi | 10.1086/505210 | en_US |
| dc.identifier.issn | 10584838 | en_US |
| dc.identifier.other | 2-s2.0-33745700384 | en_US |
| dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/23318 | |
| dc.rights | Mahidol University | en_US |
| dc.rights.holder | SCOPUS | en_US |
| dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33745700384&origin=inward | en_US |
| dc.subject | Immunology and Microbiology | en_US |
| dc.title | Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33745700384&origin=inward | en_US |